您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Epertinib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Epertinib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Epertinib图片
CAS NO:908305-13-5
包装:1mg
市场价:2200元

产品名称
S-22611
产品介绍
Epertinib (S-22611) 是一种口服有效的,可逆的,选择性的EGFRHER4HER2抑制剂,IC50值分别为 1.48 nM,2.49 nM 和 7.15 nM。Epertinib 具有高效的抗肿瘤活性。
生物活性

Epertinib (S-22611) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor ofEGFR,HER4andHER2, withIC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib shows potent antitumor activity[1][2].

IC50& Target[1]

EGFR

1.48 ± 0.0 nM (IC50)

HER4

2.49 ± 0.1 nM (IC50)

HER2

7.15 ± 0.5 nM (IC50)

体外研究
(In Vitro)

Epertinib inhibits the phosphorylation of EGFR and HER2 in NCI-N87 cells, with IC50values of 4.5 and 1.6 nM, respectively[2].
Epertinib shows inhibitory activity against MDA-MB-361 cell, with an IC50of 26.5 nM[1].
Epertinib (0-10 μM, 72 h) can selectively inhibit the proliferation of a range of cancer cell lines expressing EGFR and/or HER2[2].

Cell Proliferation Assay[2]

Cell Line:NCI-N87 (stomach), BT-474 (breast), SK-BR-3 (breast), MDA-MB-453 (breast), MDA-MB-175VII (breast), HT115 (colon), Calu-3 (lung), fR2 (breast), and MRC-5 (lung)
Concentration:0-10 μM
Incubation Time:72 h
Result:Inhibited the growth of NCI-N87, BT-474, SK-BR-3, MDA-MB-453, MDA-MB-175VII, HT115, Calu-3, fR2, and MRC-5, with IC50values of 8.3 ± 2.6, 9.9 ± 0.8, 14.0 ± 3.6, 48.6 ± 3.1, 21.6 ± 4.3, 53.3 ± 8.6, 241.5 ± 29.2, 5366.7 ± 65.2, and 4964.6 ± 340.3.
体内研究
(In Vivo)

Epertinib (0-100 mg/kg, Orally, once daily for 28 days) shows antitumor activity[1].
Epertinib (50 mg/kg, Orally, once daily for 30 days) significantly reduces the brain tumor volume[1].
Epertinib (0-50 mg/kg, Orally, once daily for 10-28 days) significantly inhibits the tumor growth in a dose-dependent manner[2].

Animal Model:Nude mice (BALB/cAJcl-nu/nu, implanted intracranially with MDA-MB-361 or BR2 cells)[1]
Dosage:12.5, 25, 50, 100 mg/kg
Administration:Orally, once daily for 28 days
Result:Showed antitumor activity in the mammary fat pad implantation model using both cell lines and the ED50values were comparable (24.1 mg/kg and 26.5 mg/kg for MDA-MB-361 and BR2 (MDA-MB-361-luc-BR2), respectively).
Animal Model:Nude mice (BALB/cAJcl-nu/nu, implanted intracranially with MDA-MB-361 or BR2 cells)[1]
Dosage:50 mg/kg
Administration:Orally, once daily for 30 days
Result:Significantly reduced the brain tumor volume, indicating that epertinib could have potent antitumor activity in brain metastasis even in the presence of an intact BTB (blood-tumor barrier).
Animal Model:Nude mice (BALB/cAJcl-nu/nu, prepared by subcutaneous implantation of human gastric cancer cells, NCI-N87 into the back of nude mice)[2]
Dosage:0, 6.25, 12.5, 25, and 50 mg/kg
Administration:Oral gavage, daily for 10-28 days
Result:Significantly inhibited the tumor growth in a dose-dependent manner.
分子量

560.02

性状

Solid

Formula

C30H27ClFN5O3

CAS 号

908305-13-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)